Calcium channel blockers and dementia

British Journal of Pharmacology

Volumn 169, Issue 6, 2013, Pages 1203-1210

  Nimmrich, V ^a   Eckert, A ^b  

^a ABBVIE INC   (United States)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Alzheimer's disease; calcium antagonists; calcium channels; vascular dementia

Indexed keywords

AMLODIPINE; AMYLOID BETA PROTEIN; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; NILVADIPINE; NIMODIPINE; NITRENDIPINE; PLACEBO; VERAPAMIL; VOLTAGE GATED CALCIUM CHANNEL;

ALZHEIMER DISEASE; ANTIHYPERTENSIVE ACTIVITY; ARTERY DILATATION; BRAIN PERFUSION; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CELL MEMBRANE; CEREBROVASCULAR DISEASE; DEMENTIA; DISEASE MODEL; DRUG RESPONSE; DRUG SELECTIVITY; EXCITOTOXICITY; HUMAN; IN VITRO STUDY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PRESYNAPTIC NERVE; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CALCIUM CHANNELS, L-TYPE; CALCIUM SIGNALING; DEMENTIA; DISEASE PROGRESSION; DRUGS, INVESTIGATIONAL; HUMANS; NEURONS; NOOTROPIC AGENTS; SYNAPTIC TRANSMISSION;

EID: 84879349584     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12240     Document Type: Review

References (90)

1. Abbadie C, McManus OB, Sun SY, Bugianesi RM, Dai G, Haedo RJ, et al. (2010). Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker. J Pharmacol Exp Ther 334: 545-555.
2. Abramov E, Dolev I, Fogel H, Ciccotosto GD, Ruff E, Slutsky I, (2009). Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. Nat Neurosci 12: 1567-1576.
3. Anekonda TS, Quinn JF, Harris C, Frahler K, Wadsworth TL, Woltjer RL, (2011). L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. Neurobiol Dis 41: 62-70.
4. Asakura K, Matsuo Y, Kanemasa T, Ninomiya M, (1997). P/Q-type Ca2+ channel blocker omega-agatoxin IVA protects against brain injury after focal ischemia in rats. Brain Res 776: 140-145.
5. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, et al. (2005). Globular amyloid beta-peptide oligomer-a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 95: 834-847.
6. Baskys A, Cheng JX, (2012). Pharmacological prevention and treatment of vascular dementia: approaches and perspectives. Exp Gerontol 47: 887-891.
7. Bell KF, Cuello C, (2006). Altered synaptic function in Alzheimer's disease. Eur J Pharmacol 545: 11-21.
8. Berman RF, Verweij BH, Muizelaar JP, (2000). Neurobehavioral protection by the neuronal calcium channel blocker ziconotide in a model of traumatic diffuse brain injury in rats. J Neurosurg 93: 821-828.
9. Bernhardt T, Kubler J, Erzigkeit H, (1995). Impairment of cerebral function in old age: nimodipine in general practice. Eur J Clin Res 7: 205-215.
10. Bliss TV, Collingridge GL, (1993). A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361: 31-39.
11. Bobich JA, Zheng Q, Campbell A, (2004). Incubation of nerve endings with a physiological concentration of Abeta1-42 activates CaV2.2(N-Type)-voltage operated calcium channels and acutely increases glutamate and noradrenaline release. J Alzheimers Dis 6: 243-255.
12. Caudle WM, Zhang J, (2009). Glutamate, excitotoxicity, and programmed cell death in Parkinson disease. Exp Neurol 220: 230-233.
13. Copenhaver PF, Anekonda TS, Musashe D, Robinson KM, Ramaker JM, Swanson TL, et al. (2011). A translational continuum of model systems for evaluating treatment strategies in Alzheimer's disease: isradipine as a candidate drug. Dis Model Mech 4: 634-648.
14. Davidson M, Stern RG, (1991). The treatment of cognitive impairment in Alzheimer's disease: beyond the cholinergic approach. Psychiatr Clin North Am 14: 461-482.
15. Davidson RM, Shajenko L, Donta TS, (1994). Amyloid beta-peptide (A beta P) potentiates a nimodipine-sensitive L-type barium conductance in N1E-115 neuroblastoma cells. Brain Res 643: 324-327.
16. Diochot S, Richard S, Baldy-Moulinier M, Nargeot J, Valmier J, (1995). Dihydropyridines, phenylalkylamines and benzothiazepines block N-, P/Q- and R-type calcium currents. Pflugers Arch 431: 10-19.
17. Eckert A, (2005). The importance of nimodipine in treatment of dementia. Pharm Unserer Zeit 34: 392-398.
18. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhäger WH, Babarskiene MR, et al. (1998). Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352: 1347-1351.
19. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al. (2002). The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 162: 2046-2052.
20. Freir DB, Costello DA, Herron CE, (2003). A beta 25-35-induced depression of long-term potentiation in area CA1 in vivo and in vitro is attenuated by verapamil. J Neurophysiol 89: 3061-3069.
21. Fu H, Li W, Lao Y, Luo J, Lee NT, Kan KK, et al. (2006). Bis(7)-tacrine attenuates beta amyloid-induced neuronal apoptosis by regulating L-type calcium channels. J Neurochem 98: 1400-1410.
22. Gellermann GP, Byrnes H, Striebinger A, Ullrich K, Mueller R, Hillen H, et al. (2008). A beta-globulomers are formed independently of the fibril pathway. Neurobiol Dis 30: 212-220.
23. Granic I, Nyakas C, Luiten PG, Eisel UL, Halmy LG, Gross G, et al. (2010). Calpain inhibition prevents amyloid-beta-induced neurodegeneration and associated behavioral dysfunction in rats. Neuropharmacology 59: 334-342.
24. Green KN, Peers C, (2001). Amyloid beta peptides mediate hypoxic augmentation of Ca(2+) channels. J Neurochem 77: 953-956.
25. Greenamyre JT, Young AB, (1989). Excitatory amino acids and Alzheimer's disease. Neurobiol Aging 10: 593-602.
26. Grosskreutz J, van Den Bosch L, Keller BU, (2010). Calcium dysregulation in amyotrophic lateral sclerosis. Cell Calcium 47: 165-174.
27. Hanyu H, Hirao K, Shimizu S, Sato T, Kiuchi A, Iwamoto T, (2007). Nilvadipine prevents cognitive decline of patients with mild cognitive impairment. Int J Geriatr Psychiatry 22: 1264-1266.
28. Hardy JA, Higgins GA, (1992). Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185.
29. Hardy JA, Selkoe DJ, (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
30. Harkany T, Abrahám I, Kõnya C, Nyakas C, Zarándi M, Penke B, et al. (2000). Mechanisms of beta-amyloid neurotoxicity: perspectives of pharmacotherapy. Rev Neurosci 11: 329-382.
31. He LM, Chen LY, Lou XL, Qu AL, Zhou Z, Xu T, (2002). Evaluation of beta-amyloid peptide 25-35 on calcium homeostasis in cultured rat dorsal root ganglion neurons. Brain Res 939: 65-75.
32. Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brickman AM, Glymour MM, et al. (2009). Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 66: 343-348.
33. Ho R, Ortiz D, Shea TB, (2001). Amyloid-beta promotes calcium influx and neurodegeneration via stimulation of L voltage-sensitive calcium channels rather than NMDA channels in cultured neurons. J Alzheimers Dis 3: 479-483.
34. Hofman A, Rocca WA, Brayne C, (1991). The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings-Eurodem Prevalence Research Group. Int J Epidemiol 20: 736-748.
35. Hogan MJ, Gjedde A, Hakin AM, (1991). In vivo binding of nimodipine in the brain: II. Binding kinetics in focal cerebral ischemia. J Cereb Blood Flow Metab 11: 771-778.
36. Hosaka T, Yamamoto YL, Diksic M, (1991). Efficacy of retrograde perfusion of the cerebral vein with verapamil after focal ischemia in rat brain. Stroke 22: 1562-1566.
37. Hunter AJ, (1997). Calcium antagonists: their role in neuroprotection. Int Rev Neurobiol 40: 95-108.
38. Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, et al. (2006). Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 103: 5161-5166.
39. Jellinger KA, (2005). The neuropathologic substrates of vascular-ischemic dementia. In:, Paul HR, (ed.). Vascular Dementia: Cerebrovascular Mechanisms and Clinical Management. Humana Press Inc.: Totowa, NJ, pp. 23-56.
40. Kasparová J, Lisá V, Tucek S, Dolezal V, (2001). Chronic exposure of NG108-15 cells to amyloid beta peptide (A beta(1-42)) abolishes calcium influx via N-type calcium channels. Neurochem Res 26: 1079-1084.
41. Kim S, Rhim H, (2011). Effects of amyloid-β peptides on voltage-gated L-type Ca(V)1.2 and Ca(V)1.3 Ca(2+) channels. Mol Cells 32: 289-294.
42. Lõpez-Arrieta JM, Birks J, (2002). Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev (3): CD000147.
43. MacManus A, Ramsden M, Murray M, Henderson Z, Pearson HA, Campbell VA, (2000). Enhancement of (45)Ca(2+) influx and voltage-dependent Ca(2+) channel activity by beta-amyloid-(1-40) in rat cortical synaptosomes and cultured cortical neurons. Modulation by the proinflammatory cytokine interleukin-1beta. J Biol Chem 275: 4713-4718.
44. Mannsvelder HD, Stoof JC, Kits KS, (1996). Dihydropyridine block of omega-agatoxin IVA-and omega-conotoxin GVIA-sensitive Ca2+ channels in rat pituitary melanotropic cells. Eur J Pharmacol 311: 293-304.
45. Mezler M, Barghorn S, Schoemaker H, Gross G, Nimmrich V, (2012). A β-amyloid oligomer directly modulates P/Q-type calcium currents in Xenopus oocytes. Br J Pharmacol 165: 1572-1583.
46. Moechars D, Dewachter I, Lorent K, Reversé D, Baekelandt V, Naidu A, et al. (1999). Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274: 6483-6492.
47. Neuropathology Group (2001). Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology group of the medical research council cognitive function and ageing study (MRC CFAS). Lancet 357: 169-175.
48. Nimmrich V, Ebert U, (2009). Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunction induced by oligomeric beta-amyloid. Rev Neurosci 20: 1-12.
49. Nimmrich V, Grimm C, Draguhn A, Barghorn S, Lehmann A, Schoemaker H, et al. (2008). Amyloid beta oligomers (A beta(1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J Neurosci 28: 788-797.
50. O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, et al. (2003). Vascular cognitive impairment. Lancet Neurol 2: 89-98.
51. Paris D, Bachmeier C, Patel N, Quadros A, Volmar CH, Laporte V, et al. (2011). Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier. Mol Med 17: 149-162.
52. Parnetti L, Senin U, Carosi M, Baasch H, (1993). Mental deterioration in old age: results of two multicenter, clinical trials with nimodipine. Clin Ther 15: 394-406.
53. Popovic̈ M, Caballero-Bleda M, Popovic̈ N, Bokonjic̈ D, Dobric̈ S, (1997). Neuroprotective effect of chronic verapamil treatment on cognitive and noncognitive deficits in an experimental Alzheimer's disease in rats. Int. J Neurosci 92: 79-93.
54. Price SA, Held B, Pearson HA, (1998). Amyloid beta protein increases Ca2+ currents in rat cerebellar granule neurones. Neuroreport 9: 539-545.
55. Querfurth HW, LaFerla FM, (2010). Alzheimer's disease. N Engl J Med 362: 329-344.
56. Ramsden M, Henderson Z, Pearson HA, (2002). Modulation of Ca2+ channel currents in primary cultures of rat cortical neurones by amyloid beta protein (1-40) is dependent on solubility status. Brain Res 956: 254-261.
57. Rocca WA, Hofman A, Brayne C, (1991). Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980-1990 prevalence findings: the EURODEM-Prevalence Research Group. Ann Neurol 30: 381-390.
58. Roman GC, (2005). Clinical forms of vascular dementia. In:, Paul HR, (ed.). Vascular Dementia: Cerebrovascular Mechanisms and Clinical Management. Humana Press Inc.: Totowa, NJ, pp. 7-21.
59. Román GC, (2002). Vascular dementia may be the most common form of dementia in the elderly. J Neurol Sci 203-204: 7-10.
60. Rovira C, Arbez N, Mariani J, (2002). Abeta(25-35) and Abeta(1-40) act on different calcium channels in CA1 hippocampal neurons. Biochem Biophys Res Commun 296: 1317-1321.
61. Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F, (2012). New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol 73: 504-517.
62. Scott VE, Vortherms TA, Niforatos W, Swensen AM, Neelands T, Milicic I, et al. (2012). A-1048400 is a novel, orally active, state-dependent neuronal calcium channel blocker that produces dose-dependent antinociception without altering hemodynamic function in rats. Biochem Pharmacol 83: 406-418.
63. Scragg JL, Fearon IM, Ball SG, Schwartz A, Varadi G, Peers C, (2004). Analysis of oxygen-sensitive human cardiac L-type Ca2+ channel alpha1C subunit (hHT Isoform). Methods Enzymol 381: 290-302.
64. Scriabine A, van den Kerckhoff W, (1988). Pharmacology of nimodipine. A review. Ann N Y Acad Sci 522: 698-706.
65. Selkoe DJ, (2008). Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 192: 106-113.
66. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL, (2007). Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27: 2866-2875.
67. Shaw PJ, Ince PG, (1997). Glutamate, excitotoxicity and amyotrophic lateral sclerosis. J Neurol 244 (Suppl. 2): S3-S14.
68. Silei V, Fabrizi C, Venturini G, Salmona M, Bugiani O, Tagliavini F, et al. (1999). Activation of microglial cells by PrP and beta-amyloid fragments raises intracellular calcium through L-type voltage sensitive calcium channels. Brain Res 818: 168-170.
69. Skoog I, (1998). Status of risk factors for vascular dementia. Neuroepidemiology 17: 2-9.
70. Small DH, Gasperini R, Vincent AJ, Hung AC, Foa L, (2009). The role of Abeta-induced calcium dysregulation in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 16: 225-233.
71. Stine WB Jr, Dahlgren KN, Krafft GA, LaDu MJ, (2003). In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem 278: 11612-11622.
72. Supnet C, Bezprozvany I, (2010). The dysregulation of intracellular calcium in Alzheimer disease. Cell Calcium 47: 183-189.
73. Suwelack D, Weber H, Maruhn D, (1985). Pharmacokinetics of Nimodipine. II. Communication: distribution, elimination and placental transfer in rats following single and multiple doses of [14C]nimodipine. Arzneimittelforschung 35: 1787-1794.
74. Takakura S, Sogabe K, Satoh H, Mori J, Fujiwara T, Totsuka Z, et al. (1992). Nilvadipine as a neuroprotective calcium entry blocker in a rat model of global cerebral ischemia. A comparative study with nicardipine hydrochloride. Neurosci Lett 141: 199-202.
75. Texidõ L, Martín-Satué M, Alberdi E, Solsona C, Matute C, (2011). Amyloid β peptide oligomers directly activate NMDA receptors. Cell Calcium 49: 184-190.
76. Toescu EC, Verkhratsky A, (2007). The importance of being subtle: small changes in calcium homeostasis control cognitive decline in normal aging. Aging Cell 6: 267-273.
77. Tomassoni D, Lanari A, Silvestrelli G, Traini E, Amenta F, (2008). Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies. Clin Exp Hypertens 30: 744-766.
78. Trompet S, Westendorp RG, Kamper AM, de Craen AJ, (2008). Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study. Neurobiol Aging 29: 306-308.
79. Uchida S, Yamada S, Nagai K, Deguchi Y, Kimura R, (1997). Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists. Life Sci 61: 2083-2090.
80. Ueda K, Shinohara S, Yagami T, Asakura K, Kawasaki K, (1997). Amyloid beta protein potentiates Ca2+ influx through L-type voltage-sensitive Ca2+ channels: a possible involvement of free radicals. J Neurochem 68: 265-271.
81. Verweij BH, Muizelaar JP, Vinas FC, Peterson PL, Xiong Y, Lee CP, (2000). Improvement in mitochondrial dysfunction as a new surrogate efficiency measure for preclinical trials: dose-response and time-window profiles for administration of the calcium channel blocker ziconotide in experimental brain injury. J Neurosurg 93: 829-834.
82. Walsh DM, Selkoe DJ, (2007). Aβ oligomers-a decade of discovery. J Neurochem 101: 1172-1184.
83. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539.
84. Wang Z, Deng Y, Zhang X, Wang T, Wu F, (2006). Development and pharmacokinetics of nimodipine-loaded liposomes. J Pharm Pharmacol 58: 1289-1294.
85. Weiss JH, Pike CJ, Cotman CW, (1994). Ca2+ channel blockers attenuate beta-amyloid peptide toxicity to cortical neurons in culture. J Neurochem 62: 372-375.
86. Yagami T, Ueda K, Asakura K, Sakaeda T, Nakazato H, Kuroda T, et al. (2002). Gas6 rescues cortical neurons from amyloid beta protein-induced apoptosis. Neuropharmacology 43: 1289-1296.
87. Yamamoto T, Takahara A, (2009). Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem 9: 377-395.
88. Yasar S, Corrada M, Brookmeyer R, Kawas C, (2005). Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging. Neurobiol Aging 26: 157-163.
89. Yu JT, Chang RC, Tan L, (2009). Calcium dysregulation in Alzheimer's disease: from mechanisms to therapeutic opportunities. Prog Neurobiol 89: 240-255.
90. Yu L, Edalji R, Harlan JE, Holzman TF, Lopez AP, Labkovsky B, et al. (2009b). Structural characterization of a soluble amyloid beta-peptide oligomer. Biochemistry 48: 1870-1877.